UK cell and gene clinical trials up 45% from 2018

cell and gene therapy Catapult revealed that there are currently 127 ongoing cell and gene trials in the UK, an increase of about 45% compared to 2018, accounting for 12% of the total number of clinical studies on cell and gene therapy worldwide.
Last year's Catapult report from Cell and Gene Therapy also documented an increase in employment in the sector, showing that the industry currently supports more than 3,000 jobs, including 1,700 in manufacturing and bio-processing.
In addition, the report shows that the UK will more than double the number of jobs in its cells and genes by 2024 as more and more therapies move towards commercialisation. Over the past seven years, the industry has expanded from 500 jobs in 2012 to more than 3,000, and is expected to reach 6,000 by 2024.
Now, the organisation's 2019 UK Advanced Therapeutics Clinical Trials Database has shown that 77 per cent of cell and gene therapy trials in the UK are sponsored by commercial organisations, compared with just 25 per cent in 2013, reflecting the company's continued investment in cells and genes.
Encouraging figures suggest that the NHS and the UK ecosystem are providing the right platform for more and more innovative therapies to be put into clinical practice.
Health Secretary Nicola Blackwood commented that the "extraordinary figures" showed life sciences in the UK were rapidly leading the way in providing cutting-edge treatment for NHS patients.
She added: "Our research capabilities continue to grow and our excellence in the NHS as a whole not only allows patients to get more innovative drugs, but also invests in companies that seek outstanding expertise." ”（cyy123.com）